Nirav Shah to Lymphoma, B-Cell
This is a "connection" page, showing publications Nirav Shah has written about Lymphoma, B-Cell.
Connection Strength
3.084
-
Salvage polatuzumab and allogeneic transplant rescue patients with B-cell lymphoma failing CAR T-cell therapy. Blood Adv. 2023 06 13; 7(11):2463-2467.
Score: 0.783
-
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. 2020 10; 26(10):1569-1575.
Score: 0.650
-
What is the standard of care for primary mediastinal B cell lymphoma; R-CHOP or DA-EPOCH-R? - Response to Melani et?al. Br J Haematol. 2019 03; 184(5):838-840.
Score: 0.544
-
R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. Br J Haematol. 2018 02; 180(4):534-544.
Score: 0.535
-
Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy. Blood Adv. 2024 05 28; 8(10):2592-2599.
Score: 0.209
-
Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL. Blood Adv. 2023 Jun 27; 7(12):2657-2669.
Score: 0.196
-
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021 03 06; 397(10277):892-901.
Score: 0.167